Application/Control Number: 10/539,219

Art Unit: 1648

The application has been amended as follows:

Claim 1 (current amended). In line 3 after "recognizes" please insert ----integrin --

Claim 2 (current amended). In line 3, please delete "is" and insert --- has --- and after "different" please insert --- serotypes ---

Claim 3 (current amended). In line 2 please substitute "comprising an" with --- maintains the ---

Claim 14 (current amended). In line 2 after "expression of " please insert ---- integrin --

Claim 36 (current amended). In line 2 and line 6 after "expressing " please insert ---integrin –

Claim 37 (current amended). In line 2 please substitute "comprising an" with --- maintains the ---

Claim 42 (current amended). In line 2 after "expression of " please insert ---- integrin –

Please cancel claims 16-35, and 50-62.

Clams 1-5, 7-15, 36-39 and 41-49 are allowed.

2. The following is an examiner's statement of reasons for allowance: No prior art teaches or suggests that certain serotypes of Echoviruses that are capable of binding to integrin $\alpha 2\beta 1$ can specifically kill cancer/tumor cell that has a high level of integrin $\alpha 2\beta 1$ expression.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."



